NCT02807558 2024-12-13A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic SyndromeSyros PharmaceuticalsPhase 2 Completed155 enrolled 24 charts